Zacks: Brokerages Anticipate X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) to Announce -$0.68 Earnings Per Share

Wall Street brokerages expect that X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) will report earnings per share of ($0.68) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for X4 Pharmaceuticals’ earnings. The highest EPS estimate is ($0.47) and the lowest is ($0.82). X4 Pharmaceuticals reported earnings of ($0.91) per share in the same quarter last year, which would indicate a positive year over year growth rate of 25.3%. The firm is scheduled to announce its next earnings report on Thursday, March 3rd.

According to Zacks, analysts expect that X4 Pharmaceuticals will report full-year earnings of ($3.06) per share for the current fiscal year, with EPS estimates ranging from ($3.42) to ($2.79). For the next year, analysts anticipate that the firm will post earnings of ($2.78) per share, with EPS estimates ranging from ($3.93) to ($2.34). Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that cover X4 Pharmaceuticals.

X4 Pharmaceuticals (NASDAQ:XFOR) last issued its earnings results on Thursday, November 4th. The company reported ($0.76) earnings per share for the quarter, missing the consensus estimate of ($0.72) by ($0.04). During the same period in the prior year, the business earned ($0.87) earnings per share.

Several research analysts have weighed in on XFOR shares. Zacks Investment Research lowered X4 Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, January 8th. HC Wainwright lowered their price objective on X4 Pharmaceuticals from $21.00 to $11.00 and set a “buy” rating on the stock in a report on Tuesday, December 14th.

Hedge funds and other institutional investors have recently modified their holdings of the company. AIGH Capital Management LLC bought a new stake in X4 Pharmaceuticals during the 2nd quarter valued at approximately $9,353,000. Altium Capital Management LP bought a new stake in X4 Pharmaceuticals during the 3rd quarter valued at approximately $4,256,000. Millennium Management LLC bought a new stake in X4 Pharmaceuticals during the 2nd quarter valued at approximately $2,509,000. Worth Venture Partners LLC bought a new stake in X4 Pharmaceuticals during the 2nd quarter valued at approximately $2,175,000. Finally, Vanguard Group Inc. boosted its stake in X4 Pharmaceuticals by 21.9% during the 2nd quarter. Vanguard Group Inc. now owns 897,641 shares of the company’s stock valued at $5,834,000 after purchasing an additional 161,039 shares during the period. 71.55% of the stock is currently owned by institutional investors and hedge funds.

XFOR stock traded down $0.08 during mid-day trading on Friday, hitting $2.09. The stock had a trading volume of 205,335 shares, compared to its average volume of 240,609. The company has a current ratio of 6.10, a quick ratio of 6.10 and a debt-to-equity ratio of 0.48. X4 Pharmaceuticals has a 1-year low of $1.80 and a 1-year high of $10.70. The company has a fifty day moving average of $3.35 and a 200 day moving average of $4.69. The stock has a market capitalization of $51.64 million, a price-to-earnings ratio of -0.56 and a beta of 0.33.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc operates as a biotechnology company, which engages in developing human antibodies for treating infectious diseases. The company focuses on restoring healthy immune system function by developing novel therapeutics for the treatment of rare diseases. Its products in pipeline include X4P-001, X4P-002, and X4P-003.

Recommended Story: What is dollar cost averaging (DCA)?

Get a free copy of the Zacks research report on X4 Pharmaceuticals (XFOR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for X4 Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for X4 Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.